Sign In
Buy AVIR
$4.99
+0.0800 (+1.63%)
At Close: Jul 10, 2026
Topline Phase 3 Results from C-FORWARD Expected Around Year-End 2026 More Than 880 HCV Treatment-Naïve Patients Enrolled Across 17 Countries Outside North America C-FORWARD and C-BEYOND Represent the
Atea Pharmaceuticals (AVIR) Upgraded to Buy: Here's What You Should Know
01:00pm, Thursday, 18'th Jun 2026
Atea Pharmaceuticals (AVIR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
10:41am, Tuesday, 09'th Jun 2026
Here is how Atea Pharmaceuticals, Inc. (AVIR) and Design Therapeutics, Inc. (DSGN) have performed compared to their sector so far this year.
Atea Pharmaceuticals: I'm Optimistic Ahead Of Critical HPV Catalyst
11:19am, Friday, 29'th May 2026
Atea Pharmaceuticals, Inc. receives a buy rating ahead of pivotal phase 3 BEM/RZR hepatitis C data expected mid-2026. AVIR's BEM/RZR targets a differentiated, short-duration, pan-genotypic HCV regimen
BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral a
Down 25% in 4 Weeks, Here's Why Atea Pharmaceuticals (AVIR) Looks Ripe for a Turnaround
10:37am, Friday, 15'th May 2026
Atea Pharmaceuticals (AVIR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts
Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline
07:00am, Wednesday, 13'th May 2026
BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral a
Atea Pharmaceuticals, Inc. (AVIR) Q1 2026 Earnings Call Transcript
12:30am, Wednesday, 13'th May 2026
Atea Pharmaceuticals, Inc. (AVIR) Q1 2026 Earnings Call Transcript
Atea Pharmaceuticals Q1 Earnings Call Highlights
06:08pm, Tuesday, 12'th May 2026
Atea Pharmaceuticals NASDAQ: AVIR said it remains on track for two key Phase 3 hepatitis C readouts in 2026 while advancing a newer hepatitis E program aimed at immunocompromised patients with no appr
Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
04:05pm, Tuesday, 12'th May 2026
C-BEYOND Phase 3 North American Trial for Treatment of Hepatitis C Virus (HCV) Remains on Track with Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial Outside North America for Treatment of HC
Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026
07:00am, Tuesday, 05'th May 2026
BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral a
Atea Pharmaceuticals (NASDAQ:AVIR) vs. Trevi Therapeutics (NASDAQ:TRVI) Financial Survey
02:08am, Thursday, 12'th Mar 2026
Trevi Therapeutics (NASDAQ: TRVI - Get Free Report) and Atea Pharmaceuticals (NASDAQ: AVIR - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast
Atea Pharmaceuticals Q4 Earnings Call Highlights
04:48am, Saturday, 07'th Mar 2026
Atea Pharmaceuticals (NASDAQ: AVIR) outlined progress in its hepatitis C (HCV) late-stage development program and provided an update on its newly expanded hepatitis E virus (HEV) pipeline during its f
Atea Pharmaceuticals, Inc. (AVIR) Q4 2025 Earnings Call Transcript
06:55pm, Thursday, 05'th Mar 2026
Atea Pharmaceuticals, Inc. (AVIR) Q4 2025 Earnings Call Transcript
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
04:05pm, Thursday, 05'th Mar 2026
Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Ou
